Hong-Li Sun1, Bing Han1, Hong-Peng Zhai2, Xin-Hua Cheng1, Kai Ma3. 1. Department of Biliary Vascular Surgery, Shenjing Hospital of China Medical University, Shenyang 110004, China. 2. Department of General Surgery, Central Hospital of Shenyang Medical College, Shenyang 110004, China. 3. Department of Biliary Vascular Surgery, Shenjing Hospital of China Medical University, Shenyang 110004, China. Electronic address: makai0311@126.com.
Abstract
BACKGROUND AND PURPOSE: Acute pancreatitis is the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP). We conducted a meta-analysis to evaluate the efficacy and safety of rectal nonsteroidal anti-inflammatory drugs (NSAIDs) for the prevention of post-ERCP pancreatitis (PEP). METHODS: PubMed and Embase databases were searched through April 2013. Results are reported as relative risk (RR) or weighted mean difference (WMD) with 95% confidence interval (95% CI). The primary outcome measure was the incidence of PEP. Secondary outcome measures included the severity of PEP and serum amylase level 2 h, 24 h after ERCP. RESULTS: Seven trials containing 1846 patients were eligible. Rectal NSAIDs significantly reduced the incidence of PEP (RR 0.45, 95% CI 0.34-0.61, P < 0.001). The results were maintained in subsequent subgroup analysis. Rectal NSAIDs also was associated with a reduction in the incidence of mild PEP (RR 0.54, 95% CI 0.35-0.83, P = 0.005), moderate to severe PEP (RR 0.39, 95% CI 0.22-0.70, P = 0.002), or serum amylase level 2 h after ERCP (WMD -91.09 IU/L, 95% CI -149.78 to -32.40, P = 0.002). CONCLUSIONS: Rectal NSAIDs reduced the incidence and severity of PEP, as well as serum amylase level 2 h after ERCP.
BACKGROUND AND PURPOSE: Acute pancreatitis is the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP). We conducted a meta-analysis to evaluate the efficacy and safety of rectal nonsteroidal anti-inflammatory drugs (NSAIDs) for the prevention of post-ERCP pancreatitis (PEP). METHODS: PubMed and Embase databases were searched through April 2013. Results are reported as relative risk (RR) or weighted mean difference (WMD) with 95% confidence interval (95% CI). The primary outcome measure was the incidence of PEP. Secondary outcome measures included the severity of PEP and serum amylase level 2 h, 24 h after ERCP. RESULTS: Seven trials containing 1846 patients were eligible. Rectal NSAIDs significantly reduced the incidence of PEP (RR 0.45, 95% CI 0.34-0.61, P < 0.001). The results were maintained in subsequent subgroup analysis. Rectal NSAIDs also was associated with a reduction in the incidence of mild PEP (RR 0.54, 95% CI 0.35-0.83, P = 0.005), moderate to severe PEP (RR 0.39, 95% CI 0.22-0.70, P = 0.002), or serum amylase level 2 h after ERCP (WMD -91.09 IU/L, 95% CI -149.78 to -32.40, P = 0.002). CONCLUSIONS: Rectal NSAIDs reduced the incidence and severity of PEP, as well as serum amylase level 2 h after ERCP.
Authors: Vilja Koskensalo; Andrea Tenca; Marianne Udd; Outi Lindström; Mia Rainio; Kalle Jokelainen; Leena Kylänpää; Martti Färkkilä Journal: United European Gastroenterol J Date: 2020-03-08 Impact factor: 4.623
Authors: John M Levenick; Stuart R Gordon; Linda L Fadden; L Campbell Levy; Matthew J Rockacy; Sarah M Hyder; Brian E Lacy; Steven P Bensen; Douglas D Parr; Timothy B Gardner Journal: Gastroenterology Date: 2016-01-09 Impact factor: 22.682
Authors: Matias E Czerwonko; Juan Pekolj; Pedro Uad; Oscar Mazza; Rodrigo Sanchez-Claria; Guillermo Arbues; Eduardo de Santibañes; Martín de Santibañes; Martín Palavecino Journal: World J Surg Date: 2018-10 Impact factor: 3.352
Authors: Noor-L-Houda Bekkali; Tom Thomas; Margaret Geraldine Keane; Sam Murray; Deepak Joshi; Ghassan Elsayed; Gavin James Johnson; Michael Huw Chapman; Stephen Paul Pereira; George John Mitchell Webster Journal: JOP Date: 2017-07-31
Authors: Giovanna Sheiybani; Peter Brydon; Miriam Toolan; John Linehan; Mark Farrant; Benjamin Colleypriest Journal: Frontline Gastroenterol Date: 2017-08-10